Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioRestorative Therapies, Inc.

Market Cap 9M 7.76M 7.14M 6.72M 12.62M 849M 12.73M 84.56M 32.92M 417M 33.77M 33.04M 1.44B P/E 2026 *
-0.71x
P/E 2027 * -0.87x
Enterprise Value 9M 7.76M 7.14M 6.72M 12.62M 849M 12.73M 84.56M 32.92M 417M 33.77M 33.04M 1.44B EV / Sales 2026 *
6.4x
EV / Sales 2027 * 3.89x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
1 day+13.14%
1 week+5.13%
Current month-16.42%
1 month+114.09%
3 months+58.41%
6 months-63.68%
Current year-66.00%
1 week 0.35
Extreme 0.3496
0.42
1 month 0.16
Extreme 0.1593
0.68
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
7.13
5 years 0.16
Extreme 0.1593
34.4
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 16/11/2020
Director of Finance/CFO 59 04/11/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 16/11/2020
Director/Board Member 60 29/10/2021
Director/Board Member 28 12/06/2026
Date Insider Type Main position Quantity % Market Cap.
06/10/25Free

Chief Technology Officer

23,438 0.2938%
06/10/25Free

Chief Executive Officer

27,344 0.3427%
14/02/25Other

Chief Technology Officer

768,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
+13.14%+5.13%-76.77%-93.35% 9M
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.04%+7.05%-12.15%-16.12% 22.63B
+3.07%+7.15%-1.82%+387.14% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
+0.65%-0.27%+26.80%+176.87% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.27%+6.06%+78.78%+103.63% 11.56B
Average +2.25%-0.89%+15.67%+70.32% 20.97B
Weighted average by Cap. +1.53%+0.18%+32.13%+90.44%

Financials

2026 *2027 *
Net sales 1.4M 1.21M 1.11M 1.05M 1.97M 133M 1.99M 13.21M 5.14M 65.08M 5.27M 5.16M 225M 2.31M 1.99M 1.83M 1.73M 3.24M 218M 3.27M 21.74M 8.46M 107M 8.68M 8.49M 371M
Net income -13.52M -11.67M -10.73M -10.1M -18.97M -1.28B -19.13M -127M -49.49M -626M -50.76M -49.67M -2.17B -15.56M -13.42M -12.34M -11.62M -21.83M -1.47B -22.01M -146M -56.93M -721M -58.39M -57.15M -2.49B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
18/06/26 0.3995 $ +13.14% 846,607
16/06/26 0.3531 $ -9.69% 778,249
15/06/26 0.3910 $ +10.92% 1,272,087
12/06/26 0.3525 $ -6.25% 828,147
11/06/26 0.3760 $ -1.05% 439,162
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3531USD
Average target price
8.000USD
Spread / Average Target
+2,165.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!